Stock Performance and Market Context
On 24 Nov 2025, Valiant Laboratories' share price recorded an intraday low of Rs.70.26, representing a fall of 3.75% during the trading session. The stock has been on a downward trajectory for two consecutive days, accumulating a loss of 7.89% over this period. This underperformance contrasts with the broader market, where the Sensex opened 88.12 points higher and was trading at 85,328.27, up 0.11%. The Sensex is also nearing its 52-week high of 85,801.70, supported by mega-cap stocks and a three-week consecutive rise amounting to 2.54% gains.
Valiant Laboratories has underperformed its sector by 2.56% today, and its current price is below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning indicates sustained downward pressure on the stock relative to its recent trading history.
Under the radar no more! This Large Cap from Cement is emerging from turnaround with solid fundamentals intact. Discover it while it's still relatively hidden!
- - Hidden turnaround gem
- - Solid fundamentals confirmed
- - Large Cap opportunity
Long-Term and Recent Financial Trends
Over the past year, Valiant Laboratories' stock has generated a return of -35.98%, a stark contrast to the Sensex's 7.87% gain during the same period. The stock's 52-week high was Rs.136.80, highlighting the extent of the decline to the current low. The company’s long-term financial indicators reveal challenges, with operating profits showing a compound annual growth rate (CAGR) of -49.92% over the last five years. This negative trend in operating profits suggests persistent pressure on the company’s earnings capacity.
Valiant Laboratories’ ability to service its debt is reflected in an average EBIT to interest ratio of 0.65, indicating limited coverage of interest expenses by earnings before interest and taxes. Additionally, the company’s average return on equity (ROE) stands at 0.80%, signalling modest profitability relative to shareholders’ funds. The latest reported ROE is 1.6%, while the stock trades at a price-to-book value of 1.3, which is considered relatively expensive compared to its peers’ historical valuations.
Profitability and Sales Growth
Despite the stock’s price decline, the company has reported positive results for the last three consecutive quarters. Net sales for the latest six-month period reached Rs.93.02 crores, reflecting a growth rate of 130.48%. Profit after tax (PAT) for the same period was Rs.2.02 crores, indicating an improvement in absolute profitability. However, these gains have not translated into positive stock performance, as the market continues to weigh other factors.
Valiant Laboratories’ price-to-earnings-to-growth (PEG) ratio is 0.6, which suggests that the stock is trading at a discount relative to its earnings growth. Nevertheless, the stock’s returns over the last three years, one year, and three months have lagged behind the BSE500 index, underscoring a pattern of underperformance in both the near and longer term.
Shareholding and Market Capitalisation
The majority of Valiant Laboratories’ shares are held by promoters, indicating concentrated ownership. The company’s market capitalisation grade is rated at 4, reflecting its size and market presence within the Pharmaceuticals & Biotechnology sector.
Why settle for Valiant Laboratories ? SwitchER evaluates this Pharmaceuticals & Biotechnology micro-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Sector and Market Comparison
Within the Pharmaceuticals & Biotechnology sector, Valiant Laboratories’ recent stock performance contrasts with the broader market’s positive momentum. While the Sensex and mega-cap stocks have shown resilience and gains, Valiant Laboratories remains below key technical levels and continues to face valuation pressures. The stock’s discount to peer valuations may reflect market caution given the company’s financial metrics and historical returns.
Summary of Key Price and Performance Metrics
Valiant Laboratories’ current stock price of Rs.70.26 is its lowest in 52 weeks and all-time trading history. The stock’s decline over the past year amounts to nearly 36%, while the Sensex has recorded gains close to 8% in the same timeframe. The company’s operating profit trend, debt servicing capacity, and return on equity figures provide context for the stock’s subdued performance. Despite recent sales and profit growth, the stock remains below all major moving averages, signalling continued downward momentum.
Investors and market participants will note the divergence between the company’s improving sales and profit figures and the stock’s price trajectory, which has not yet reflected these operational developments.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
